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Clinical PerspectiveWhat Is New?Claims data are often used for postmarket surveillance of coronary stents.The extent to which adverse events (repeat percutaneous coronary intervention, myocardial infarction, and death) identified with claims data can be attributed to a previously placed stent is uncertain.By linking Medicare claims with a national registry of percutaneous coronary interventions, we found that only half of repeat percutaneous coronary interventions, one‐fourth of myocardial infarctions, and 1% of deaths identified with claims data within 1 year after index percutaneous coronary intervention could be attributed to a previously placed coronary drug‐eluting stent.What Are the Clinical Implications?Although real‐world data sources, such as claims, are increasingly important for longitudinal postmarket surveillance of medical devices, including coronary stents, claims data alone may be insufficient to ascertain stent safety and may only serve as a signal for further evaluation.Postmarket surveillance would be strengthened with complementary data sources, in addition to claims, to evaluate stent safety.

Introduction {#jah34843-sec-0008}
============

In recent years, the US Food and Drug Administration has increasingly shifted toward a life‐cycle regulatory approach for medical devices,[1](#jah34843-bib-0001){ref-type="ref"}, [2](#jah34843-bib-0002){ref-type="ref"} allowing the agency more flexibility in premarket clinical trial requirements with greater reliance on longitudinal postmarket surveillance to confirm and continue to reassess safety and effectiveness. The recent creation of the National Evaluation System for health Technology is intended to promote the use of real‐world evidence to support medical device regulatory evaluations,[3](#jah34843-bib-0003){ref-type="ref"} and the US Food and Drug Administration recently released a Guidance Document[4](#jah34843-bib-0004){ref-type="ref"} about how real‐world evidence can support medical device regulatory decision making. An important and frequently used source of data for these purposes is administrative claims,[5](#jah34843-bib-0005){ref-type="ref"} which are billing data collected by health plans that include basic demographic and clinical information, as well as longitudinal information on clinical encounters, as long as patients have continuous coverage with the same health plan aggregating the claims. Although their ubiquity makes claims data attractive,[6](#jah34843-bib-0006){ref-type="ref"} they have important limitations, not unlike other real‐world evidence sources.[5](#jah34843-bib-0005){ref-type="ref"} These data are not principally designed to support research[5](#jah34843-bib-0005){ref-type="ref"}; lack detailed clinical information; and may not include all of the diagnoses or procedures performed during a hospitalization or clinic visit.[7](#jah34843-bib-0007){ref-type="ref"} With respect to safety surveillance, claims data have been used with the hope that relevant outcomes can be identified from claims and be reasonably attributed to medical device performance. For claims data to be useful for this purpose, it is critical to know whether adverse events identified using claims data can be reasonably attributed to the medical device in question.

Coronary stents play a key role in the revascularization of patients with coronary artery disease. In 2014, over 667 000 percutaneous coronary interventions (PCIs), \>90% of which include stent placement,[8](#jah34843-bib-0008){ref-type="ref"} were recorded in the National Cardiovascular Data Registry (NCDR) CathPCI Registry,[9](#jah34843-bib-0009){ref-type="ref"} which includes \>90% of PCI‐capable hospitals in the United States. However, important safety concerns pertaining to coronary stents have been discovered since their original approval, including late‐stent thrombosis among drug‐eluting stents (DESs),[10](#jah34843-bib-0010){ref-type="ref"} higher thrombosis and myocardial infarction (MI) risk associated with bioresorbable vascular scaffolds,[11](#jah34843-bib-0011){ref-type="ref"} and in‐stent restenosis, a progressive narrowing from vascular remodeling and neointimal hyperplasia.[12](#jah34843-bib-0012){ref-type="ref"} Despite these concerns, coronary stent surveillance has been challenging because there is no established surveillance system and it is unknown how often the clinical sequelae of these safety‐related adverse events that can be identified in claims data, such as need for repeat coronary revascularization, can be reasonably attributed to a previously placed stent.

Coronary stents thus offer a unique opportunity to better understand the utility of claims data to characterize medical‐device--related adverse events because they are commonly implanted and existing data sources containing detailed information on coronary stent implantations have been linked to administrative claims. Specifically, the NCDR CathPCI Registry includes detailed patient, clinical, and procedural information---including coronary artery--level data---for patients receiving PCI. These data have been linked to longitudinal claims data from the Centers for Medicare and Medicaid Services (CMS) to allow identification of adverse events, which can, in turn, be evaluated to determine whether they are related to previous coronary stent placement.

Accordingly, we sought to assess the extent to which a repeat PCI identified using claims data could be reasonably attributed to the same coronary artery in which a coronary stent was first implanted (ie, target vessel revascularization \[TVR\]). We focused on TVR because it is an end point frequently used to assess coronary stent safety postimplantation. We did this by identifying index DES placements from the NCDR CathPCI Registry, characterizing incidence of safety‐related adverse events during 1 year of patient follow‐up using Medicare fee‐for‐service (FFS) claims data and then linking those patients who experienced safety‐related adverse events in claims back to the NCDR CathPCI Registry. We also sought to understand what characteristics are associated with greater attribution of a repeat PCI to the artery that had previously received a stent, given that those factors could help target surveillance efforts. We focused on DES given that the vast majority of PCIs involve DES placement. Results from this study can inform our ability to use claims data for ascertainment of stent safety as a part of real‐world postmarket device surveillance.

Methods {#jah34843-sec-0009}
=======

This study was approved by the Yale University Human Investigation Committee; informed consent for the purpose of this project was not required. The study was approved by the NCDR and the CathPCI Research & Publications Committee reviewed the final manuscript before submission, but had no role in the design, conduct, or reporting of the study. Requests to access the CathPCI data that were used for this study can be sent to the American College of Cardiology\'s NCDR at <ncdr@acc.org>; <https://cvquality.acc.org/NCDR-Home/registries/hospital-registries/cathpci-registry>.

Data Sources {#jah34843-sec-0010}
------------

The CathPCI Registry, an initiative sponsored by the American College of Cardiology Foundation and the Society for Cardiovascular Angiography and Interventions, is the largest PCI registry in the United States, used in \>90% of PCI‐capable hospitals[9](#jah34843-bib-0009){ref-type="ref"} and has been described previously.[13](#jah34843-bib-0013){ref-type="ref"}, [14](#jah34843-bib-0014){ref-type="ref"} Data on patient demographics, comorbidities, episode of care, and procedural data are included from hospitalization during which PCI is performed. A data quality program ensures reliable and consistent data.[15](#jah34843-bib-0015){ref-type="ref"} All data elements are recorded by trained abstractors and electronically forwarded to a secure data server. Institutions had to meet NCDR quality criteria for reporting to be included.

We identified longitudinal outcomes in inpatient and outpatient institutional claims for Medicare FFS beneficiaries using *International Classification of Diseases*,*Ninth Revision*,*Clinical Modification* (*ICD‐9‐CM*) codes. These data sets contain claims for inpatient admissions and outpatient care, including procedures for Medicare FFS patients. Additionally, we used 2009--2014 Medicare Beneficiary Summary Files to obtain FFS enrollment and the postdischarge vital status of each beneficiary. We linked Medicare inpatient and outpatient institutional claims to the NCDR CathPCI Registry using deterministic matching on Social Security number, date of birth, and sex.

Study Population {#jah34843-sec-0011}
----------------

We identified all patients aged ≥65 years who underwent a DES implantation from July 1, 2009 and December 31, 2013, were linked to CMS claims data, and who were continuously enrolled in FFS Part A and B for 1 year following the index procedure or until the date of death if they died within the year after the procedure (Figure [1](#jah34843-fig-0001){ref-type="fig"}). Patients aged ≥65 years who cannot be linked to CMS claims data are likely enrolled in the Medicare Advantage program.[16](#jah34843-bib-0016){ref-type="ref"} We excluded patients who received both a bare‐metal stent and a DES, multiple DESs at 1 visit in different coronary arteries, or a single DES that crossed \>1 of the 4 major epicardial coronary arteries (left main, left anterior descending, left circumflex, and right coronary artery) because attribution to a single stent in a single vessel would be more challenging. We included patients who received multiple DESs at 1 visit within the same coronary artery as a single implant.

![Flow diagram of included drug‐eluting stent placements. BMS indicates bare‐metal stent; CMS, Centers for Medicare and Medicaid Services; DES, drug‐eluting stent; FFS, fee‐for‐service; PCI, percutaneous coronary intervention; SSN, Social Security number.](JAH3-9-e013606-g001){#jah34843-fig-0001}

Outcomes and Definitions {#jah34843-sec-0012}
------------------------

We aimed to characterize the proportion of repeat PCIs within 1 year of index DES implantation that represented TVR. We chose to focus first on TVR, instead of target lesion revascularization, because lesion information may be inconsistently reported, particularly for patients who receive multiple procedures from multiple providers.

We first identified subsequent PCIs in CMS claims in the year after an index PCI using *ICD‐9‐CM* procedure codes or Current Procedural Terminology codes (see Table [S1](#jah34843-sup-0001){ref-type="supplementary-material"} for *ICD‐9‐CM*/CPT codes). We subsequently linked these claims back to the CathPCI Registry to determine which vessel was revascularized. For all analyses, we defined TVR as an unstaged repeat PCI performed in the same vessel treated during the index PCI. Branch vessels were all collapsed to the primary epicardial coronary artery because our analysis was conducted at the vessel level (eg, diagonal vessels were considered part of the left anterior descending system and obtuse marginals were considered part of the left circumflex system). We considered a repeat PCI staged if it occurred within 60 days of the index PCI given that ≤25% of staged PCIs occur \>1 month after index PCI,[17](#jah34843-bib-0017){ref-type="ref"} and did not have a primary discharge diagnosis code of myocardial infarction (MI) or any other diagnostic code suggesting a procedural complication. We still followed patients identified as having a staged PCI after 60 days for subsequent revascularization, MI, or death within 1 year of the index procedure.

Among those identified as TVR, we also examined whether the repeat PCI was performed on a specific lesion that had been previously stented with a DES and, if so, we categorized it as attributable to either in‐stent restenosis or stent thrombosis.

We also characterized MI and death in the year following the index PCI.[18](#jah34843-bib-0018){ref-type="ref"} Although many causes of MI or death are not likely stent related, we still examined both because these are the most important clinical events that can be secondary to stent‐related complications, and these are the types of adverse events commonly used by regulators to ascertain medical product safety. We identified MI using *ICD‐9‐CM* primary discharge diagnosis codes during a subsequent hospitalization. We obtained dates of death from the master summary beneficiary file.

For patients for whom repeat revascularization and MI events were identified from Medicare claims, we further sought to understand whether baseline patient demographic, clinical, and procedural characteristics were associated with successful attribution to the same coronary artery in which a DES had been previously placed.

Patient, Clinical, and Procedural Characteristics of Interest {#jah34843-sec-0013}
-------------------------------------------------------------

We identified multiple patient, clinical, or procedural characteristics of interest (Table [1](#jah34843-tbl-0001){ref-type="table"}). These included patient demographics, cardiovascular history, and other relevant clinical history. We also included procedural and hospital characteristics from the episode of care associated with the original PCI and stent implantation, as well as characteristics of the coronary artery in which the stent was implanted. If 2 DESs were placed in the same artery, their lengths were added, ignoring potential overlap between stents. Among previously treated lesions, we determined whether previous PCI included a stent and, if so, whether the index procedure was performed for in‐stent restenosis or in‐stent thrombosis.

###### 

Patient, Procedural, and Vessel Characteristics

                                                            No.       \%
  --------------------------------------------------------- --------- ----------------
  N procedures                                              415 306   
  Demographics                                                        
  Age, y, mean (SD)                                         74.23     6.56
  Sex: female                                               158 086   38.06
  Race                                                                
  White                                                     381 545   91.87
  Black                                                     21 220    5.11
  Asian                                                     6022      1.45
  Other                                                     6519      1.57
  Hispanic or Latino ethnicity                              14 571    3.51
  Cardiovascular history                                              
  Previous MI                                               127 114   30.62
  Previous HF                                               60 661    14.61
  Previous valve surgery/procedure                          7984      1.92
  Cerebrovascular disease                                   67 995    16.38
  Peripheral arterial disease                               66 436    16.00
  NYHA class (among those with HF in previous 2 wk)                   
  I                                                         4674      10.22
  II                                                        13 751    30.06
  III                                                       17 451    38.15
  IV                                                        9866      21.57
  Cardiomyopathy or left ventricular systolic dysfunction   47 157    11.36
  Cardiogenic shock w/in 24 h                               4642      1.12
  Cardiac arrest w/in 24 h                                  4303      1.04
  Other clinical history                                              
  Current/recent smoker (w/in 1 y)                          53 226    12.82
  Hypertension                                              363 037   87.44
  Dyslipidemia                                              347 251   83.68
  Currently on dialysis                                     9598      2.31
  Chronic lung disease                                      73 070    17.60
  Diabetes mellitus                                         157 748   38.00
  Procedure characteristics                                           
  CAD presentation                                                    
  No symptoms, no angina                                    37 350    9.00
  Symptoms unlikely to be ischemic                          12 652    3.05
  Stable angina                                             79 185    19.07
  Unstable angina                                           176 881   42.60
  NSTEMI                                                    70 514    16.98
  STEMI or equivalent                                       38 639    9.31
  Previous PCI                                              190 461   45.87
  Previous CABG                                             98 158    23.64
  Diagnostic Cath status                                              
  Elective                                                  177 098   50.68
  Urgent                                                    129 045   36.93
  Emergency                                                 42 815    12.25
  Salvage                                                   472       0.14
  Procedure year                                                      
  2009                                                      43 280    10.42
  2010                                                      100 041   24.09
  2011                                                      89 269    21.49
  2012                                                      91 086    21.93
  2013                                                      91 630    22.06
  PCI status                                                          
  Elective                                                  208 464   50.22
  Urgent                                                    162 300   39.10
  Emergency                                                 43 759    10.54
  Salvage                                                   611       0.15
  IABP                                                      5240      1.26
  Other mechanical ventricular support                      1381      0.33
  Multivessel disease                                       208 373   50.17
  Vessel characteristics                                              
  No. of stents placed, median (IQR)                        1.00      (1.00--2.00)
  Sum of stent diameter, median (IQR)                       3.00      (2.75--5.00)
  Sum of stent length, median (IQR)                         22.00     (15.00--33.00)
  Stent length categorized                                            
  Short (≤16 mm)                                            141 135   34.02
  Medium (\>16--28 mm)                                      146 361   35.28
  Long (\>28 mm)                                            127 332   30.70
  Mean vessel stenosis before Tx, median (IQR)              90.00     (80.00--95.00)
  Preprocedure TIMI flow                                              
  TIMI---0                                                  37 967    9.17
  TIMI---1                                                  32 786    7.92
  TIMI---2                                                  82 852    20.00
  TIMI---3                                                  260 598   62.92
  Previously treated lesion                                 50 666    12.21
  Among previously treated lesions                                    
  Previously treated lesion time frame                                
  \<1 mo                                                    1994      3.94
  1 to 5 mo                                                 5668      11.21
  6 to 12 mo                                                6370      12.60
  1 to 2 y                                                  7209      14.26
  \>2 y                                                     25 365    50.16
  Time unknown                                              3959      7.83
  Treated with stent                                        47 152    93.19
  In‐stent restenosis                                       43 445    92.19
  In‐stent thrombosis                                       4613      9.80
  Lesion in graft                                                     
  Not in graft                                              377 850   91.02
  Vein                                                      34 644    8.35
  LIMA graft                                                1854      0.45
  Other artery                                              795       0.19
  Lesion complexity                                                   
  Non‐high/non‐C                                            190 068   45.80
  High/C                                                    224 936   54.20
  Maximum lesion length, median (IQR), mm                   18.00     (12.00--24.00)
  Thrombus present                                          41 432    9.98
  Bifurcation lesion                                        50 592    12.19

CABG indicates coronary artery bypass graft; CAD, coronary artery disease; Cath, catheterization; HF, heart failure; IABP, intra‐aortic balloon pump; IQR, interquartile range; LIMA, left internal mammary artery; MI, myocardial infarction; NSTEMI, non--ST‐segment--elevation myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction; Tx, treatment.

Statistical Analysis {#jah34843-sec-0014}
--------------------

We estimated the proportion of patients for whom potential stent‐related safety events (TVR, MI, and death) identified from Medicare claims could be attributed to the same coronary artery in which a DES had been previously placed, overall and stratified by the individual safety end points: TVR, MI, and death. For patients with multiple safety events identified after stent implantation, we analyzed events separately. We performed a sensitivity analysis for patients without a history of previous PCI. We used χ^2^ tests for categorical variables and Wilcoxon or *t* tests for continuous variables. We considered comparisons significant at *P*\<0.05. For analyses examining whether baseline patient demographic, clinical, and procedural characteristics were associated with successful attribution, we did not correct for multiple comparisons because these analyses were considered exploratory.

Results {#jah34843-sec-0015}
=======

Study Cohort {#jah34843-sec-0016}
------------

Between July 1, 2009 and December 31, 2013, 919 636 patients aged ≥65 years identified in the CathPCI Registry received a total 1 208 454 DES placements during 1 056 056 PCI procedures (Figure [1](#jah34843-fig-0001){ref-type="fig"}). We excluded 27 085 DES placements for left main bifurcation lesions, 17 077 multivessel PCIs with inability to identify which vessel received the DES, and 278 747 in which multiple DESs were implanted into \>1 coronary artery. Next, we excluded 251 951 DES placements in patients who could not be linked to CMS data for longitudinal follow‐up (this includes patients enrolled in Medicare Advantage plans, Medicaid plans, other state‐sponsored plans, or employer‐based insurance), 611 without CMS FFS information, and 217 677 who did not have continuous Part A and B FFS enrollment for 1 year post‐PCI. Our final sample of NCDR‐Medicare FFS‐linked data included 415 306 index DES placements in 368 194 patients at 1380 hospitals.

Patient and Procedural Characteristics {#jah34843-sec-0017}
--------------------------------------

Mean age of patients undergoing PCI in our cohort was 74.2 years, 38.1% were female, and 91.9% were white (Table [1](#jah34843-tbl-0001){ref-type="table"}). Furthermore, 30.6% of patients had a history of previous MI, 45.9% previous PCI, and 23.6% previous coronary artery bypass graft. Unstable angina was coronary artery disease presentation in 42.6%, non--ST‐segment--elevation myocardial infarction in 17.0%, and ST‐segment--elevation myocardial infarction (STEMI) in 9.3%. At the index PCI, a median of 1 stent was placed (interquartile range, 1--2), with median stent length of 22 mm (interquartile range, 15--33). Twelve percent of lesions had been previously treated, half of which occurred \>2 years before the index PCI; of these previously treated lesions, 92.2% were for in‐stent restenosis and 9.8% for in‐stent thrombosis.

Of the 415 306 DES placements in 368 194 patients, 61 409 (14.8%) were found to have had any adverse event identified within CMS claims data within 1 year: repeat PCI, MI, or death. Of these, 28 607 (46.6%) were successfully linked back to the NCDR CathPCI Registry, including angiographic data, because the patients underwent coronary angiography and/or PCI at the time of the adverse event. Patients for whom angiographic data could be linked were younger and more often male, less commonly had heart failure, cerebrovascular disease, cardiogenic shock, cardiac arrest, presentation with STEMI, and were less often urgent or emergency procedures compared with patients for whom angiographic data were unavailable (Table [S2](#jah34843-sup-0001){ref-type="supplementary-material"}).

Adverse Events Linked From CMS Claims to the NCDR CathPCI Registry {#jah34843-sec-0018}
------------------------------------------------------------------

### Target vessel revascularization {#jah34843-sec-0019}

Of the 415 306 DES placements in 368 194 patients, 33 174 (8.0%) were followed by repeat PCIs identified in CMS claims data (not considered staged PCIs) within 1 year (Figure [2](#jah34843-fig-0002){ref-type="fig"}). Of these, 28 632 (86.3%) were successfully linked back to NCDR CathPCI Registry data because the patient received diagnostic coronary angiography and/or PCI, 28 453 (85.8%) included data on coronary anatomy, and 16 942 (51.1%) were attributed to the same coronary artery treated during the index PCI (ie, TVR). Of the 16 942 TVRs, 9954 (58.8%) could be identified as having been inserted within a previously placed stent; of these, 1410 were previously placed bare metal stents and 8544 (50.4%) were previously placed DESs. Among the latter, 7652 were TVRs for in‐stent restenosis and 1341 for stent thrombosis. Overall results of the proportion of patients with TVR were consistent in a sensitivity analysis of patients without a history of previous PCI (Figure [S1](#jah34843-sup-0001){ref-type="supplementary-material"}).

![Attribution of adverse events identified in Medicare claims data after index drug‐eluting stent placement in patients aged ≥65 years, 2009--2013. AEs indicates adverse events; MI, myocardial infarction; NCDR, National Cardiovascular Data Registry; PCI, percutaneous coronary intervention.](JAH3-9-e013606-g002){#jah34843-fig-0002}

### Myocardial infarction {#jah34843-sec-0020}

Of the 415 306 DES placements in 368 194 patients, 16 176 (3.9%) were followed by acute MIs identified in CMS claims data within 1 year (Figure [2](#jah34843-fig-0002){ref-type="fig"}). Of these, 8693 (53.7%) were successfully linked to NCDR CathPCI Registry data because the patient received diagnostic coronary angiography and/or PCI, 6856 (42.4%) included data on coronary anatomy from PCI, and 4446 (27.5%) were attributed to the same coronary artery in which the stent was implanted during the index PCI (ie, target vessel MI), and 2410 could not be attributed to that same coronary artery. In total, of the 6856 DES placements that were followed by acute MIs identified in CMS claims data with NCDR CathPCI data available on patients' coronary anatomy from PCI, 4446 (64.8%) were attributed to the same coronary artery in which the stent was implanted during the index PCI.

### Death {#jah34843-sec-0021}

Of the 415 306 DES placements in 368 194 patients, 24 288 (5.8%) were followed by patient death identified in CMS claims data within 1 year. Of these, 466 (1.9%) could be successfully linked to NCDR CathPCI Registry data because the patient received diagnostic coronary angiography and/or PCI, 390 (1.6%) included data on coronary anatomy from PCI, and 278 (1.1%) were attributed to the same coronary artery in which the DES was implanted during the index PCI, and 112 could not be attributed to that same coronary artery. In total, of the 390 DES placements that were followed by patient death identified in CMS claims data with NCDR CathPCI data available on coronary anatomy from PCI, 278 (71.3%) were attributed to the same coronary artery in which the stent was implanted during the index PCI.

Association Between Index PCI Characteristics and Attribution of Repeat PCI or MI {#jah34843-sec-0022}
---------------------------------------------------------------------------------

In exploratory analyses, several patient and procedural characteristics were associated with higher rates of successful attribution of a repeat PCI or MI identified from claims data to the same coronary artery as the originally placed DES, including previous MI, previous PCI before index stent placement, and previous coronary artery bypass grafting (Tables [2](#jah34843-tbl-0002){ref-type="table"} and [3](#jah34843-tbl-0003){ref-type="table"}). Time from index to repeat PCI was also significantly associated with attribution: PCIs and MIs identified before 30 or \>90 days after index PCI were more frequently attributed compared with PCIs between 31 and 90 days (repeat PCI: 54.6% for \<30 days versus 37.5% between 31 and 90 days versus 53.4% \>90 days after index PCI; *P*\<0.001). Total length of stent(s) placed at index PCI \>28 mm was associated with greater attribution compared with shorter total stent lengths (repeat PCI: 53.5% for \>28 mm versus 50.3% for ≤16 mm and 49.3% for \>16--28 mm; *P*\<0.001).

###### 

Association of Patient, Procedural, Vessel, and Hospital Characteristics With Attribution of Repeat PCI Events to Index Vessel

                                                            Overall   Not Attributed   Attributed   *P* Value                    
  --------------------------------------------------------- --------- ---------------- ------------ ----------- -------- ------- ---------
  N procedures                                              33 174                     16 232       48.93       16 942   51.07   
  Demographics                                                                                                                   
  Age, y, mean (SD)                                         73.86     6.36             73.95                    73.77            0.020
  Sex: female                                               12 234    36.88            6035         49.33       6199     50.67   0.265
  Race                                                                                                                           0.007
  White                                                     30 225    91.11            14 752       48.81       15 473   51.19   
  Black                                                     1915      5.77             924          48.25       991      51.75   
  Asian                                                     495       1.49             277          55.96       218      44.04   
  Other                                                     539       1.62             279          51.76       260      48.24   
  Cardiovascular history                                                                                                         
  Previous MI                                               12 701    38.30            5854         46.09       6847     53.91   \<0.001
  Previous HF                                               5803      17.50            2733         47.10       3070     52.90   0.002
  Cerebrovascular disease                                   6662      20.09            3115         46.76       3547     53.24   \<0.001
  Peripheral arterial disease                               6909      20.83            3101         44.88       3808     55.12   \<0.001
  NYHA class (among those with HF in past 2 wk)                                                                                  0.545
  I                                                         396       10.66            197          49.75       199      50.25   
  II                                                        1132      30.48            567          50.09       565      49.91   
  III                                                       1415      38.10            670          47.35       745      52.65   
  IV                                                        771       20.76            372          48.25       399      51.75   
  Cardiomyopathy or left ventricular systolic dysfunction   3969      11.97            1893         47.69       2076     52.31   0.097
  Other clinical history                                                                                                         
  Current/recent smoker (w/in 1 y)                          3781      11.40            1972         52.16       1809     47.84   \<0.001
  Hypertension                                              30 198    91.06            14 671       48.58       15 527   51.42   \<0.001
  Dyslipidemia                                              28 999    87.49            13 969       48.17       15 030   51.83   \<0.001
  Chronic lung disease                                      5954      17.95            2874         48.27       3080     51.73   0.261
  Diabetes mellitus                                         15 585    46.99            7308         46.89       8277     53.11   \<0.001
  Procedure characteristics                                                                                                      
  CAD presentation                                                                                                               \<0.001
  No symptoms, no angina                                    2205      6.65             1198         54.33       1007     45.67   
  Stable angina                                             6021      18.15            3055         50.74       2966     49.26   
  Unstable angina                                           15 874    47.86            7434         46.83       8440     53.17   
  NSTEMI                                                    5955      17.96            2847         47.81       3108     52.19   
  STEMI or equivalent                                       2396      7.22             1324         55.26       1072     44.74   
  Previous PCI                                              20 071    60.51            9130         45.49       10 941   54.51   \<0.001
  Previous CABG                                             12 096    36.47            5091         42.09       7005     57.91   \<0.001
  Diagnostic Cath status                                                                                                         \<0.001
  Elective                                                  13 771    49.09            6723         48.82       7048     51.18   
  Urgent                                                    11 399    40.64            5276         46.28       6123     53.72   
  Emergency                                                 2871      10.23            1537         53.54       1334     46.46   
  Salvage                                                   11        0.04             9            81.82       2        18.18   
  Procedure year                                                                                                                 0.335
  2009                                                      3712      11.19            1826         49.19       1886     50.81   
  2010                                                      8046      24.25            3895         48.41       4151     51.59   
  2011                                                      7010      21.13            3378         48.19       3632     51.81   
  2012                                                      7243      21.83            3578         49.40       3665     50.60   
  2013                                                      7163      21.59            3555         49.63       3608     50.37   
  PCI status                                                                                                                     \<0.001
  Elective                                                  16 137    48.66            8003         49.59       8134     50.41   
  Urgent                                                    14 055    42.38            6629         47.16       7426     52.84   
  Emergency                                                 2944      8.88             1578         53.60       1366     46.40   
  Salvage                                                   25        0.08             18           72.00       7        28.00   
  Multivessel disease                                       21 553    64.97            11 002       51.05       10 551   48.95   \<0.001
  Repeat PCI                                                                                                                     
  Time from index to repeat PCI                                                                                                  \<0.001
  ≤30 d                                                     2248      6.78             1021         45.42       1227     54.58   
  31 to 90 d                                                4943      14.90            3090         62.51       1853     37.49   
  \>90 d                                                    25 983    78.32            12 121       46.65       13 862   53.35   
  Vessel characteristics                                                                                                         
  No. of stents placed, median (IQR)                        1.00      (1.00--2.00)     1.00                     1.00             \<0.001
  Sum of stent diameter, median (IQR)                       3.00      (2.50--3.50)     3.00                     3.00             0.472
  Sum of stent length, median (IQR)                         23.00     (15.00--36.00)   23.00                    23.00            \<0.001
  Stent length categorized                                                                                                       \<0.001
  Short (≤16 mm)                                            10 128    30.56            5034         49.70       5094     50.30   
  Medium (\>16--28 mm)                                      11 218    33.85            5690         50.72       5528     49.28   
  Long (\>28 mm)                                            11 790    35.58            5488         46.55       6302     53.45   
  Mean vessel stenosis before Tx, median (IQR)              90.00     (80.00--95.00)   90.00                    90.00            0.009
  Previously treated lesion                                 6720      20.26            2414         35.92       4306     64.08   \<0.001
  Among previously treated lesions                                                                                               
  Previously treated lesion time frame                                                                                           \<0.001
  \<1 mo                                                    258       3.85             105          40.70       153      59.30   
  1 to 5 mo                                                 1073      16.00            338          31.50       735      68.50   
  6 to 12 mo                                                1077      16.06            338          31.38       739      68.62   
  1 to 2 y                                                  1046      15.60            363          34.70       683      65.30   
  \>2 y                                                     2679      39.94            1038         38.75       1641     61.25   
  Time unknown                                              574       8.56             224          39.02       350      60.98   
  Treated with stent                                        6295      93.76            2229         35.41       4066     64.59   0.001
  In‐stent restenosis                                       5875      93.42            2062         35.10       3813     64.90   0.040
  In‐stent thrombosis                                       538       8.56             220          40.89       318      59.11   0.005
  Lesion in graft                                                                                                                \<0.001
  Not in graft                                              27 675    83.46            14 066       50.83       13 609   49.17   
  Vein                                                      5106      15.40            1998         39.13       3108     60.87   
  LIMA graft                                                253       0.76             105          41.50       148      58.50   
  Other artery                                              124       0.37             58           46.77       66       53.23   
  Lesion complexity                                                                                                              \<0.001
  Non‐high/non‐C                                            13 558    40.89            6805         50.19       6753     49.81   
  High/C                                                    19 600    59.11            9418         48.05       10 182   51.95   
  Maximum lesion length, median (IQR)                       18.00     (12.00--26.00)   18.00                    18.00            \<0.001
  Thrombus present                                          3004      9.06             1546         51.46       1458     48.54   0.004
  Bifurcation lesion                                        4082      12.31            1905         46.67       2177     53.33   0.002
  Hospital characteristics                                                                                                       
  Hospital location                                                                                                              0.006
  Rural                                                     4293      12.94            2165         50.43       2128     49.57   
  Suburban                                                  10 140    30.57            5036         49.66       5104     50.34   
  Urban                                                     18 741    56.49            9031         48.19       9710     51.81   
  Profit type                                                                                                                    0.828
  Government                                                409       1.23             195          47.68       214      52.32   
  Private/community                                         29 092    87.70            14 249       48.98       14 843   51.02   
  University                                                3673      11.07            1788         48.68       1885     51.32   
  Teaching Hospital                                         15 537    46.83            7448         47.94       8089     52.06   \<0.001
  PCI count, median (IQR)                                   850.00    (500--1347)      835.00                   864.50           \<0.001

CABG indicates coronary artery bypass graft; CAD, coronary artery disease; Cath, catheterization; HF, heart failure; IQR, interquartile range; LIMA, left internal mammary artery; MI, myocardial infarction; NSTEMI, non--ST‐segment--elevation myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; Tx, treatment.

###### 

Patient, Procedural, Vessel, and Hospital Characteristics of PCIs With Attributed AMI Events

                                                            Overall   Not Attributed   Attributed   *P* Value                    
  --------------------------------------------------------- --------- ---------------- ------------ ----------- -------- ------- ---------
  N procedures                                              16 176                     11 730       72.51       4446     27.49   
  Demographics                                                                                                                   
  Age, y, mean (SD)                                         74.91     6.79             75.10                    74.39            \<0.001
  Sex: female                                               6549      40.49            4770         72.84       1779     27.16   0.451
  Race                                                                                                                           0.364
  White                                                     14 386    88.93            10 427       72.48       3959     27.52   
  Black                                                     1219      7.54             872          71.53       347      28.47   
  Asian                                                     280       1.73             210          75.00       70       25.00   
  Other                                                     291       1.80             221          75.95       70       24.05   
  Cardiovascular history                                                                                                         
  Previous MI                                               7199      44.52            5059         70.27       2140     29.73   \<0.001
  Previous HF                                               4108      25.41            3039         73.98       1069     26.02   0.015
  Cerebrovascular disease                                   3784      23.41            2712         71.67       1072     28.33   0.183
  Peripheral arterial disease                               4012      24.82            2867         71.46       1145     28.54   0.086
  NYHA class (among those with HF in past 2 wk)                                                                                  0.640
  I                                                         248       8.50             180          72.58       68       27.42   
  II                                                        766       26.24            587          76.63       179      23.37   
  III                                                       1170      40.08            882          75.38       288      24.62   
  IV                                                        735       25.18            554          75.37       181      24.63   
  Cardiomyopathy or left ventricular systolic dysfunction   2671      16.52            1955         73.19       716      26.81   0.389
  Other clinical history                                                                                                         
  Current/recent smoker (w/in 1 y)                          2312      14.30            1688         73.01       624      26.99   0.563
  Hypertension                                              14 749    91.21            10 641       72.15       4108     27.85   \<0.001
  Dyslipidemia                                              13 746    85.06            9860         71.73       3886     28.27   \<0.001
  Chronic lung disease                                      3556      22.00            2623         73.76       933      26.24   0.002
  Diabetes mellitus                                         8446      52.22            6012         71.18       2434     28.82   0.060
  Procedure characteristics                                                                                                      
  CAD presentation                                                                                                               \<0.001
  No symptoms, no angina                                    944       5.84             696          73.73       248      26.27   
  Stable angina                                             1860      11.50            1345         72.31       515      27.69   
  Unstable angina                                           6068      37.52            4194         69.12       1874     30.88   
  NSTEMI                                                    5126      31.70            3794         74.01       1332     25.99   
  STEMI or equivalent                                       1911      11.82            1511         79.07       400      20.93   
  Previous PCI                                              9153      56.60            6339         69.26       2814     30.74   \<0.001
  Previous CABG                                             6035      37.32            4137         68.55       1898     31.45   \<0.001
  Diagnostic Cath status                                                                                                         \<0.001
  Elective                                                  4563      33.33            3146         68.95       1417     31.05   
  Urgent                                                    6973      50.93            5051         72.44       1922     27.56   
  Emergency                                                 2148      15.69            1662         77.37       486      22.63   
  Salvage                                                   7         0.05             6            85.71       1        14.29   
  Procedure year                                                                                                                 0.149
  2009                                                      1543      9.54             1130         73.23       413      26.77   
  2010                                                      3562      22.02            2622         73.61       940      26.39   
  2011                                                      3449      21.32            2472         71.67       977      28.33   
  2012                                                      3739      23.11            2733         73.09       1006     26.91   
  2013                                                      3883      24.00            2773         71.41       1110     28.59   
  PCI status                                                                                                                     \<0.001
  Elective                                                  5484      33.92            3855         70.30       1629     29.70   
  Urgent                                                    8434      52.16            6126         72.63       2308     27.37   
  Emergency                                                 2231      13.80            1728         77.45       503      22.55   
  Salvage                                                   20        0.12             16           80.00       4        20.00   
  Multivessel disease                                       10 733    66.35            7729         72.01       3004     27.99   0.044
  Repeat PCI                                                                                                                     
  Time from index to repeat PCI                                                                                                  \<0.001
  ≤30 d                                                     3537      21.87            2741         77.50       796      22.50   
  31 to 90 d                                                3013      18.63            2410         79.99       603      20.01   
  \>90 d                                                    9626      59.51            6579         68.35       3047     31.65   
  Vessel characteristics                                                                                                         
  No. of stents placed, median (IQR)                        1.00      (1.00--2.00)     1.00                     1.00             \<0.001
  Sum of stent diameter, median (IQR)                       3.00      (2.75--5.50)     3.00                     3.50             \<0.001
  Sum of stent length, median (IQR)                         23.00     (15.00--36.00)   23.00                    24.00            \<0.001
  Stent length categorized                                                                                                       \<0.001
  Short (≤16 mm)                                            5038      31.17            3747         74.37       1291     25.63   
  Medium (\>16--28 mm)                                      5486      33.94            4026         73.39       1460     26.61   
  Long (\>28 mm)                                            5640      34.89            3946         69.96       1694     30.04   
  Mean vessel stenosis before Tx, median (IQR)              90.00     (80.00--95.00)   90.00                    90.00            0.104
  Previously treated lesion                                 3027      18.72            1923         63.53       1104     36.47   \<0.001
  Among previously treated lesions                                                                                               
  Previously treated lesion time frame                                                                                           0.009
  \<1 mo                                                    142       4.70             99           69.72       43       30.28   
  1 to 5 mo                                                 529       17.50            314          59.36       215      40.64   
  6 to 12 mo                                                457       15.12            286          62.58       171      37.42   
  1 to 2 y                                                  408       13.50            259          63.48       149      36.52   
  \>2 y                                                     1209      39.99            802          66.34       407      33.66   
  Time unknown                                              278       9.20             159          57.19       119      42.81   
  Treated with stent                                        2828      93.49            1793         63.40       1035     36.60   0.657
  In‐stent restenosis                                       2607      92.25            1649         63.25       958      36.75   0.546
  In‐stent thrombosis                                       326       11.55            213          65.34       113      34.66   0.434
  Lesion in graft                                                                                                                \<0.001
  Not in graft                                              13 257    81.98            9807         73.98       3450     26.02   
  Vein                                                      2725      16.85            1796         65.91       929      34.09   
  LIMA graft                                                119       0.74             72           60.50       47       39.50   
  Other artery                                              70        0.43             51           72.86       19       27.14   
  Lesion complexity                                                                                                              \<0.001
  Non‐high/non‐C                                            6397      39.58            4741         74.11       1656     25.89   
  High/C                                                    9764      60.42            6977         71.46       2787     28.54   
  Maximum lesion length, median (IQR)                       18.00     (12.00--26.00)   18.00                    18.00            \<0.001
  Thrombus present                                          2011      12.45            1523         75.73       488      24.27   \<0.001
  Bifurcation lesion                                        2022      12.51            1428         70.62       594      29.38   0.041
  Hospital characteristics                                                                                                       
  Hospital location                                                                                                              0.024
  Rural                                                     2402      14.85            1796         74.77       606      25.23   
  Suburban                                                  4798      29.66            3473         72.38       1325     27.62   
  Urban                                                     8976      55.49            6461         71.98       2515     28.02   
  Profit type                                                                                                                    0.394
  Government                                                165       1.02             117          70.91       48       29.09   
  Private/community                                         14 031    86.74            10 153       72.36       3878     27.64   
  University                                                1980      12.24            1460         73.74       520      26.26   
  Teaching Hospital                                         8090      50.01            5898         72.90       2192     27.10   0.266
  PCI count, median (IQR)                                   800.00    (476--1300)      795.00                   803.00           0.011

AMI indicates acute myocardial infarction; CABG, coronary artery bypass graft; CAD, coronary artery disease; Cath, catheterization; HF, heart failure; IQR, interquartile range; LIMA, left internal mammary artery; MI, myocardial infarction; NSTEMI, non--ST‐segment--elevation myocardial infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction; Tx, treatment.

Discussion {#jah34843-sec-0023}
==========

Only half of all PCIs performed in the year after patients received a DES placement could be reasonably attributable to the same coronary artery as the index procedure, and even fewer were attributed to the same lesion as a previously placed stent. MIs and deaths can be reasonably attributable to a previously placed stent even less frequently. Whereas exploratory analyses showed that some patient and procedural characteristics were associated with higher rates of attribution, including the timing of when the event was observed, these findings suggest that using claims data alone for surveillance may be insufficient to ascertain stent safety. Rather, postmarket surveillance efforts would likely be strengthened by the use of complementary data sources, in addition to claims, when evaluating medical device safety.

Although real‐world data sources, such as claims and registries, are increasingly important for postmarket surveillance of medical devices,[4](#jah34843-bib-0004){ref-type="ref"} our study suggests that claims data alone may be inadequate for stent surveillance unless paired with additional data sources. The US Food and Drug Administration has recently stated its goal to be first among the world\'s regulatory agencies to identify and act upon safety signals, which involves supporting implementation of the National Evaluation System for health Technology to leverage real‐world data for surveillance.[19](#jah34843-bib-0019){ref-type="ref"} Claims are ubiquitous and longitudinal, but lack the granularity of registries. Registries are a key data source for surveillance. The Medical Device Epidemiology Network is focused on creation of coordinated registry networks for several device types, including cardiovascular devices, to provide evidence across a device\'s total product life cycle.[20](#jah34843-bib-0020){ref-type="ref"} However, registries often do not include longitudinal follow‐up data (such as the CathPCI Registry),[21](#jah34843-bib-0021){ref-type="ref"} and thus claims data are often used. Claims data have been shown to be concordant between physician‐adjudication and administrative claims for some events such as mortality and heart failure hospitalization.[22](#jah34843-bib-0022){ref-type="ref"} These real‐world data sources differ from clinical trials for stents, where specific stent‐related outcomes (such as stent thrombosis or in‐stent restenosis) or outcomes specific to the vessel that had received PCI (such as TVR) are ascertained and independently adjudicated to determine whether they meet criteria for standardized definitions.[18](#jah34843-bib-0018){ref-type="ref"} However, costs, complexity, and duration make performing clinical trials infeasible to generate evidence in some circumstances[23](#jah34843-bib-0023){ref-type="ref"}; therefore, real‐world data sources will continue to be increasingly leveraged to provide evidence of benefits and risks of therapies,[21](#jah34843-bib-0021){ref-type="ref"} and we need to understand how to use claims and registries to refine estimates of device safety. Furthermore, some rare adverse events may never be detected in clinical trials, given that trials include fewer patients than when devices are used in real‐world clinical practice as well as shorter follow‐up durations for devices---which may be implanted lifelong.

Although claims are the most ubiquitous source of longitudinal real‐world data and offer opportunity with their size and completeness of the study populations, they also have important limitations when used for stent surveillance, or any other medical device surveillance. First, they may not always be accurate.[24](#jah34843-bib-0024){ref-type="ref"} One study showed that claims diagnoses codes for acute MI had a 94% positive predictive value for the same diagnosis when compared with electronic health record data.[25](#jah34843-bib-0025){ref-type="ref"} When compared with a clinical trial with end‐point adjudication, the kappa statistic was 0.76 for acute MI identified in *International Classification of Diseases*,*Ninth Revision* (*ICD‐9*) claims.[26](#jah34843-bib-0026){ref-type="ref"} Second, they lack granular detail about PCI location. *International Classification of Diseases*,*Tenth Revision* (*ICD‐10*) codes came into use in the United States from October 2015 and include 5 times as many diagnoses and 18 times as many procedures as the previously used *ICD‐9* codes, including greater detail about the number of sites in which stents are placed, stent restenosis, stent thrombosis, and stent fracture. However, *ICD‐10* codes still do not provide information about which coronary artery receives PCI.[27](#jah34843-bib-0027){ref-type="ref"} The possible exception is STEMI, for which *ICD‐10* codes detail the level of the culprit coronary artery which, presumably, would receive intervention. However, 50% of patients with STEMI have multivessel disease,[28](#jah34843-bib-0028){ref-type="ref"} and other coronary arteries may also receive stent placement during primary PCI for STEMI based on guideline recommendations.[29](#jah34843-bib-0029){ref-type="ref"} This means that although the utility of claims data identified in our study may improve with the transition to *ICD‐10*, the extent of improvement requires further study. Third, claims data are currently available in finalized form only after a ≈2‐year delay; to be used more effectively, they will also need to be made available more quickly. Fourth, and most critically for identifying stents of a specific manufacturer or model, claims data do not include unique device identifiers for medical devices. Unique device identifiers are barcodes that contain information about a device manufacturer, model, description, and other characteristics.[30](#jah34843-bib-0030){ref-type="ref"}, [31](#jah34843-bib-0031){ref-type="ref"} If unique device identifiers become included into claims data, specific stents and other implanted medical devices could be tracked longitudinally for surveillance purposes.[32](#jah34843-bib-0032){ref-type="ref"}

Although linking claims to the CathPCI Registry helps understand whether repeat PCI is TVR, this approach is still insufficient to comprehensively understand the multiple clinical factors that determine stent safety. Patient, physician, and hospital characteristics are associated with usage of certain stents and adverse events; this means that risk standardization is necessary for surveillance. However, the lack of detailed clinical data when using administrative claims as the longitudinal data source makes this inadequate at the patient level. For example, patient adherence to thienopyridines declines within 1 year, thus increasing the risk of stent thrombosis.[33](#jah34843-bib-0033){ref-type="ref"} Therefore, surveillance of DES using real‐world data could be made more robust through combination with additional data sources such as electronic health records, pharmacy claims data, and patient‐reported data.

Whereas mortality is arguably the most important clinical end point for DES safety, not unexpectedly, we could only determine that ≈1% of deaths identified in claims could be reasonably attributed to a complication within the same coronary artery in which the index PCI was performed. Because CathPCI Registry data are available for patients with documented PCI and sometimes diagnostic coronary angiography, we cannot ascertain the reason for death identified in claims for the vast majority of patients because these patients died outside of the hospital or even when hospitalized and did not receive coronary angiography and/or PCI. Some of these deaths could have been stent‐related, such as stent thrombosis leading to acute MI and sudden cardiac death. When patients had a documented repeat PCI but died, 71.4% were in the same coronary artery as was initially stented. As with death, there is incomplete attribution of MIs to previously placed stents, such as patients who experienced an MI and did not receive medical care, did not receive diagnostic coronary angiography, or did not receive PCI. Real‐world safety evaluations will often use death and MI as end points, given their clinical significance and the ease with which they can be ascertained from nationally representative claims data, but will also lack the capacity for adjudication as is done in clinical trials. Therefore, our finding that only a small proportion represent adverse events that can be attributable to previously placed stents means that these claims‐based end points can only serve as a signal that must be further evaluated and refined with complementary data sources.

Our findings may be considered in the context of several limitations. First, we excluded patients receiving multivessel PCI, which is performed in a substantial minority of cases. When multiple coronary arteries receive PCI, attribution of stent‐related safety events will be more difficult. Second, we excluded patients with repeat procedures within 60 days unless they had an MI code or complication code. Although we presumed that most of these patients were receiving staged PCI,[17](#jah34843-bib-0017){ref-type="ref"} we still may have missed some stent‐related complications, particularly if a repeat PCI occurred within the same coronary artery as the index PCI. Third, we did not include in‐hospital stent‐related adverse events, which are nearly always stent thrombosis. Claims data preclude distinguishing index from repeat PCI within a given hospitalization. Fourth, we did not examine coronary artery bypass grafting in longitudinal follow‐up, which may infrequently be a reason for revascularization after a stent‐related adverse event. Fifth, we did not examine patients longitudinally in the NCDR CathPCI Registry and then attempt to locate a corresponding CMS claim. Sixth, although the CathPCI Registry captures granular information on the coronary segment in which a device is used, these data are inconsistently reported and unlikely to be reliable. For that reason, we instead focused on the less‐granular TVR, making our estimates a "better" case scenario for attribution of adverse events to a previously placed stent. Seventh, we did not evaluate adverse events occurring because of operator‐level variation in performance of PCI. Finally, our findings are applicable only to coronary stents, given that a comprehensive national registry exists to capture PCI and the expected adverse events can be captured within claims data.

In conclusion, by linking longitudinal claims data to a comprehensive national registry of PCIs multiple times, we found that approximately half of repeat PCIs within 1 year occur in the same coronary artery as the initial PCI with DES placement, indicating a DES‐related adverse event. MI and death, although more clinically important, could be attributed much less often to the same coronary artery as the index PCI. These findings suggest that using claims data for surveillance of DESs, even when linked to a national PCI registry, may be insufficient. As momentum grows to leverage real‐world data for medical device surveillance, these limitations will need to be surmounted through novel strategies to bring together complementary data sources to inform a robust postmarket surveillance system.
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